The scheme aims to avoid disruption in supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs
Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
Commercial production is expected to begin soon
Extended lab space for product development, customer demos, and training
The GMP-compliant facility with automated environmental monitoring accommodates both white room and class 7 and 8 cleanroom space
The company received one observation in the Form-483
The project will be instrumental in enhancing the company's API manufacturing capacity and global reach
The company received 1 (One) observation in the Form-483
Zydus receives EIR for the API manufacturing facility at Ankleshwar
Subscribe To Our Newsletter & Stay Updated
